Vaxcyte logo

VaxcyteNASDAQ: PCVX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 June 2020

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$12.61 B
-4%vs. 3y high
94%vs. sector
-vs. 3y high
-vs. sector
-39%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 116 min ago
$112.94+$0.62(+0.55%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PCVX Latest News

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
globenewswire.com11 September 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
seekingalpha.com08 September 2024 Sentiment: POSITIVE

Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com06 September 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
seekingalpha.com06 September 2024 Sentiment: POSITIVE

Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering
marketwatch.com06 September 2024 Sentiment: NEUTRAL

Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high
reuters.com05 September 2024 Sentiment: POSITIVE

Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.

Vaxcyte Announces Pricing of $1.3 Billion Public Offering
globenewswire.com04 September 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
zacks.com04 September 2024 Sentiment: POSITIVE

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower
schaeffersresearch.com03 September 2024 Sentiment: POSITIVE

Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older.

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine
reuters.com03 September 2024 Sentiment: POSITIVE

Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to rival Pfizer's shot.

  • 1(current)

What type of business is Vaxcyte?

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

What sector is Vaxcyte in?

Vaxcyte is in the Healthcare sector

What industry is Vaxcyte in?

Vaxcyte is in the Biotechnology industry

What country is Vaxcyte from?

Vaxcyte is headquartered in United States

When did Vaxcyte go public?

Vaxcyte initial public offering (IPO) was on 12 June 2020

What is Vaxcyte website?

https://vaxcyte.com

Is Vaxcyte in the S&P 500?

No, Vaxcyte is not included in the S&P 500 index

Is Vaxcyte in the NASDAQ 100?

No, Vaxcyte is not included in the NASDAQ 100 index

Is Vaxcyte in the Dow Jones?

No, Vaxcyte is not included in the Dow Jones index

When was Vaxcyte the previous earnings report?

No data

When does Vaxcyte earnings report?

The next expected earnings date for Vaxcyte is 06 November 2024